

Company:

"SOPHARMA" AD

Board of Directors:

**Ognian Donev, PhD
Vessela Stoeva
Alexander Chaushev
Ognian Palaveev
Ivan Badinski**

Executive Director:

Ognian Donev, PhD

Finance Director:

Boris Borisov

Chief Accountant:

Jordanka Petkova

Registered Office:

**Sofia
16, Iliensko Shousse Str.**

Lawyers:

**Adriana Baleva
Venelin Gachev
Ventsislav Stoev
Boiko Botev
Elena Golemanova
Petar Kalpakchiev**

Servicing Banks:

**Raiffeisenbank (Bulgaria) EAD
DSK Bank EAD
Eurobank Bulgaria AD
ING Bank N.V. - Sofia Branch
UniCredit Bulbank AD
Societe General Expressbank AD
Citibank N.A.
Cibank EAD**

Auditors:

Baker Tilly Clitou and Partners OOD

"SOPHARMA" AD**INDIVIDUAL STATEMENT OF COMPREHENSIVE INCOME**

for the period ended on 31 March 2020

	Notes	2020 BGN'000	2019 BGN'000
Revenue	3	50 170	52 174
Other operating income/(losses), net	4	1 129	920
Changes in inventories of production and work in progress		2 511	3 337
Raw materials and consumables used	5	(17 901)	(19 157)
Hired services expense	6	(8 877)	(7 789)
Employee benefits expense	7	(12 958)	(12 316)
Depreciation and amortisation expense	13,14	(4 520)	(4 540)
Other operating expenses	8,9	(542)	(496)
Profit from operations		9 012	12 133
Finance income	10	1 062	2 462
Finance costs	11	(404)	(309)
Finance income / (costs), net		658	2 153
Profit before income tax		9 670	14 286
Income tax expense		(990)	(1 392)
Net profit for the year		8 680	12 894
Other comprehensive income:			
<i>Items that will not be reclassified to profit or loss:</i>			
Net change in the fair value of other long-term equity investments	18	(875)	55
Other comprehensive income for the year, net of tax	12	(875)	55
TOTAL COMPREHENSIVE INCOME FOR THE YEAR		7 805	12 949
Basic net earnings per share	26	0,07	0,10

The accompanying notes on pages 5 to 123 form an integral part of the individual financial statements.

Executive Director:

Ognian Donev, PhD

Finance Director:

Boris Borisov

Chief Accountant: :

Jordanka Petkova

"SOPHARMA" AD**INDIVIDUAL STATEMENT OF FINANCIAL POSITION**

as at 31 March 2020

	Notes	31 March 2020 BGN'000	31 March 2019 BGN'000
ASSETS			
Non-current assets			
Property, plant and equipment	13	224 294	224 654
Intangible assets	14	8 278	8 524
Investment property	15	41 083	39 329
Investments in subsidiaries	16	87 146	87 146
Investments in associates	17	6 062	6 062
Other long-term equity investments	18	10 136	9 621
Long-term receivables from related parties	19	92 686	91 794
Other long-term receivables	20	10 541	9 897
		480 226	477 027
Current assets			
Inventories	21	66 844	61 365
Receivables from related parties	22	107 632	97 014
Trade receivables	23	20 249	27 212
Loans granted to third parties	24 (a)	5 769	6 044
Other receivables and prepayments	24 (b)	12 315	6 144
Cash and cash equivalents	25	3 902	3 959
		216 711	201 738
TOTAL ASSETS		696 937	678 765
EQUITY AND LIABILITIES			
Equity attributable to equity holders of the parent			
Share capital		134 798	134 798
Treasury shares		(34 142)	(34 142)
Reserves		381 565	382 549
Retained earnings		48 228	39 439
	26	530 449	522 644
LIABILITIES			
Non-current liabilities			
Long-term bank loans	27	596	2 398
Deferred tax liabilities	28	6 185	6 209
Government grants	29	4 743	4 858
Lease liabilities to related parties	30	1 394	1 610
Lease liabilities to third parties	31	1 002	954
Retirement benefit obligations	32	4 551	4 638
		18 471	20 667
Current liabilities			
Short-term bank loans	33	107 717	100 359
Current portion of long-term bank loans	27	7 174	7 181
Trade payables	34	8 045	6 074
Payables to related parties	35	7 798	6 664
Tax payables	36	4 055	2 329
Payables to personnel and for social security	37	7 876	7 266
Other current liabilities	38	5 352	5 581
		148 017	135 454
TOTAL LIABILITIES		166 488	156 121
TOTAL EQUITY AND LIABILITIES		696 937	678 765

The accompanying notes on pages 5 to 123 form an integral part of the individual financial statements.

Executive Director:

Ognian Donev, PhD

Finance Director:

Boris Borisov

Chief Accountant: :

Jordanka Petkova

"SOPHARMA" AD**INDIVIDUAL STATEMENT OF CASH FLOWS
for the period ended on 31 March 2020**

	Notes	2020 BGN'000	2019 BGN'000
Cash flows from operating activities			
Cash receipts from customers		51 664	51 105
Cash paid to suppliers		(30 598)	(28 568)
Cash paid to employees and for social security		(12 268)	(11 372)
Taxes paid (except income taxes)		(1 611)	(1 864)
Taxes refunded (except income taxes)		1 394	284
Income taxes (paid)/refunded, net		-	(457)
Interest and bank charges paid on working capital loans		(391)	(266)
Foreign currency exchange gains/(losses), net		(55)	(53)
Other proceeds/(payments), net		(6 002)	(291)
Net cash flows from operating activities		2 133	8 518
Cash flows from investing activities			
Purchases of property, plant and equipment		(2 695)	(2 674)
Proceeds from sales of property, plant and equipment		59	9
Purchases of intangible assets		(17)	-
Purchased of investment property		(1 750)	(136)
Purchases of shares in associates		-	(135)
Proceeds from sales of shares in associates		1	99
Purchases of equity investments		(1 417)	(1 447)
Proceeds from sales of equity investments		26	87
Purchases of stocks/shares in subsidiaries		-	(181)
Proceeds from sales of stocks/shares in subsidiaries		-	1 200
Loans granted to related parties		(1 547)	(71 280)
Loan repayments by related parties		731	11 217
Loans granted to other companies		(509)	(1 078)
Loan repayments by other companies		298	2 384
Interest received on granted loans		64	531
Net cash flows used in investing activities		(6 756)	(61 404)
Cash flows from financing activities			
Repayment of long-term bank loans		(1 802)	(1 799)
Proceeds from short-term bank loans (overdraft), net		7 400	47 873
Interest and charges paid under investment purpose loans		(40)	(69)
Proceeds from sales of treasury shares		-	(2)
Dividends paid		(512)	(8)
Lease payments to related parties		(262)	(262)
Lease payments to third parties		(222)	(110)
Government grants		4	-
Net cash flows from financing activities		4 566	45 623
Net decrease in cash and cash equivalents		(57)	(7 263)
Cash and cash equivalents at 1 January		3 959	8 971
Cash and cash equivalents at 31 March	25	3 902	1 708

The accompanying notes on pages 5 to 123 form an integral part of the individual financial statements.

Executive Director:

Ognian Donev, PhD

Finance Director:

Boris Borisov

Chief Accountant:

Jordanka Petkova

"SOPHARMA" AD

INDIVIDUAL STATEMENT OF CHANGES IN EQUITY

for the period ended on 31 March 2020

	Notes	Share capital	Treasury shares	Statutory reserves	Revaluation reserve - property, plant and equipment	Reserve from financial assets at fair value through other comprehensive income	Translation of foreign operations	Retained earnings	Total
		BGN'000	BGN'000	BGN'000	BGN'000	BGN'000	BGN'000	BGN'000	BGN'000
Balance at 1 January 2019	26	134 798	(33 337)	55 967	22 433	2 933	275 977	30 448	489 219
Changes in equity for 2019									
Effect of pay back treasury shares incl:		-	(805)	-	-	-	-	-	(805)
* acquisition of treasury shares		-	(805)	-	-	-	-	-	(805)
Distribution of profit for:		-	-	3 330	-	-	22 362	(31 976)	(6 284)
* reserves		-	-	3 330	-	-	22 362	(25 692)	-
* 6-month dividends on 2019 profit		-	-	-	-	-	-	(6 284)	(6 284)
Total comprehensive income for the year, including:		-	-	-	176	(60)	-	40 398	40 514
* net profit for the year		-	-	-	-	-	-	40 382	40 382
* other comprehensive income, net of taxes		-	-	-	176	(60)	-	16	132
Transfer to retained earnings		-	-	-	(569)	-	-	569	-
Balance at 31 December 2019	26	134 798	(34 142)	59 297	22 040	2 873	298 339	39 439	522 644
Total comprehensive income for the year, including:		-	-	-	-	(875)	-	8 680	7 805
* net profit for the year		-	-	-	-	-	-	8 680	8 680
* other comprehensive income, net of taxes		-	-	-	-	(875)	-	-	(875)
Transfer to retained earnings		-	-	-	(189)	80	-	109	-
Balance as at 31 March 2020	26	134 798	(34 142)	59 297	21 851	2 078	298 339	48 228	530 449

The accompanying notes on pages 5 to 123 form an integral part of the individual financial statements.

Executive Director:

Ognian Donev, PhD

Finance Director:

Boris Borisov

Chief Accountant:

Jordanka Petkova